Sugi Predict

Sugi Predict / Compounds / SCHEMBL446560

SCHEMBL446560

SCHEMBL446560

CC(NC(=O)C1CCCN(CC(c2ccccc2)c2ccccc2)C1)c1cncn1Cc1ccc(C#N)cc1

nearest known ligand 0.45

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
▸ FNTA P49354 14/20 0.45
▸ FNTB P49356 14/20 0.45
▸ PGGT1B P53609 11/20 0.44
▸ CCR5 P51681 2/20 0.44
▸ KCNH2 Q12809 1/20 0.44
▸ CCR2 P41597 1/20 0.43
▸ KMT2A Q03164 1/20 0.43
▸ CYP11B1 P15538 1/20 0.43
▸ CYP11B2 P19099 1/20 0.43
▸ ALOX12 P18054 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8095468 0.96 FNTA (0.43) FNTAFNTBPGGT1BCCR5KCNH2
SCHEMBL8097931 0.95 KMT2A (0.51) FNTAFNTBPGGT1BCCR5KCNH2
SCHEMBL8097456 0.94 FNTA (0.44) FNTAFNTBPGGT1BCCR5KCNH2
SCHEMBL8095888 0.94 FNTA (0.42) FNTAFNTBPGGT1BCCR5KCNH2
SCHEMBL8101380 0.94 FNTA (0.43) FNTAFNTBPGGT1BCCR5KCNH2
SCHEMBL8095560 0.93 FNTA (0.41) FNTAFNTBPGGT1BCCR5KCNH2
SCHEMBL8095903 0.92 CYP11B1 (0.45) FNTAFNTBPGGT1BKCNH2CYP11B1
SCHEMBL8088415 0.92 KDM4E (0.41) FNTAFNTBPGGT1BCCR5KCNH2
SCHEMBL8104352 0.91 FNTA (0.43) FNTAFNTBPGGT1BCCR5KCNH2
SCHEMBL8088439 0.88 FNTA (0.52) FNTAFNTBPGGT1BKCNH2CYP11B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 423 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140301976-A1 NOVEL HYDROXAMATES AS THERAPEUTIC AGENTS PHARMACYCLICS, INC. 2014-10-09 — — US claimed
US-8779171-B2 Hydroxamates as therapeutic agents PHARMACYCLICS, INC. (US) 2014-07-15 — — US claimed
US-20130142758-A1 NOVEL HYDROXAMATES AS THERAPEUTIC AGENTS PHARMACYCLICS, INC. (US) 2013-06-06 — — US claimed
EP-0862435-A4 INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE MERCK & CO INC (US) 1999-02-03 — — EP claimed
EP-0862435-A1 INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE Merck & Co., Inc. (US) 1998-09-09 — — EP claimed
WO-1997018813-A1 INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE MERCK & CO., INC. (US) 1997-05-29 — — WO claimed
US-20260000691-A1 COMPOUNDS, METHODS, AND TREATMENTS FOR ABNORMAL SIGNALING PATHWAYS FOR PRENATAL AND POSTNATAL DEVELOPMENT JENNINGS BARBARA BROOKE (US) 2026-01-01 — — US disclosed
US-12329766-B2 Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development JENNINGS BARBARA BROOKE (US) 2025-06-17 — — US disclosed
EP-4552697-A2 PROTEIN KINASE C INHIBITORS AND METHODS OF THEIR USE Novartis AG (CH) 2025-05-14 — — EP disclosed
EP-3514151-B1 PROTEIN KINASE C INHIBITORS AND METHODS OF THEIR USE NOVARTIS AG (CH) 2025-04-23 — — EP disclosed
US-20240308979-A1 PROTEIN KINASE C INHIBITORS AND METHODS OF THEIR USE NOVARTIS AG (CH) 2024-09-19 — — US disclosed
US-20220110954-A1 COMPOUNDS, METHODS, AND TREATMENTS FOR ABNORMAL SIGNALING PATHWAYS FOR PRENATAL AND POSTNATAL DEVELOPMENT JENNINGS BARBARA BROOKE (US) 2022-04-14 — — US disclosed
US-11059804-B2 Protein kinase C inhibitors and methods of their use NOVARTIS AG (CH) 2021-07-13 — — US disclosed
US-6245759-B1 PYRAZOLO(1,5-A)PYRIMIDINE DERIVATIVES; ANTICARCINOGENIC AND ANTITUMOR AGENTS; ATHEROSCLEROSIS, ANGIOGENESIS INHIBITORS MERCK & CO., INC. 2001-06-12 — — US disclosed
WO-2001028993-A2 TYROSINE KINASE INHIBITORS MERCK & CO. INC. (US) 2001-04-26 — — WO disclosed
WO-2001029025-A2 TYROSINE KINASE INHIBITORS MERCK & CO., INC. (US) 2001-04-26 — — WO disclosed
WO-2001017995-A1 TYROSINE KINASE INHIBITORS MERCK & CO., INC. (US) 2001-03-15 — — WO disclosed
US-6127366-A ANTICARCINOGENIC OR ANTITUMOR AGENTS MERCK & CO., INC. (US) 2000-10-03 — — US disclosed
WO-2000053605-A1 TYROSINE KINASE INHIBITORS MERCK & CO., INC. (US) 2000-09-14 — — WO disclosed
WO-2000016778-A1 A METHOD OF TREATING CANCER MERCK & CO., INC. (US) 2000-03-30 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240308979-A1 PROTEIN KINASE C INHIBITORS AND METHODS OF THEIR USE PRKCA, PRKCB, PRKCH FNTA 1583/4885FNTB 1494/4885PGGT1B 2063/4885
US-20130142758-A1 NOVEL HYDROXAMATES AS THERAPEUTIC AGENTS HDAC1, HDAC3, HDAC5 FNTA 3317/4885FNTB 1753/4885PGGT1B 715/4885
US-20220110954-A1 COMPOUNDS, METHODS, AND TREATMENTS FOR ABNORMAL SIGNALING PATHWAYS FOR PRENATAL AND POSTNATAL DEVELOPMENT PDK1, PKM, PDK2 FNTA 3930/4885FNTB 2686/4885PGGT1B 4596/4885
US-20260000691-A1 COMPOUNDS, METHODS, AND TREATMENTS FOR ABNORMAL SIGNALING PATHWAYS FOR PRENATAL AND POSTNATAL DEVELOPMENT PDK1, IP6K1, IP6K3 FNTA 3572/4885FNTB 2992/4885PGGT1B 3876/4885
US-20140301976-A1 NOVEL HYDROXAMATES AS THERAPEUTIC AGENTS HDAC1, HDAC3, HDAC5 FNTA 3317/4885FNTB 1753/4885PGGT1B 715/4885
US-11059804-B2 Protein kinase C inhibitors and methods of their use PRKCA, PRKCB, PRKCH FNTA 1583/4885FNTB 1494/4885PGGT1B 2063/4885
US-12329766-B2 Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development PDK1, PKM, PDK2 FNTA 3930/4885FNTB 2686/4885PGGT1B 4596/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.